Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 9/20 | 0.49 |
| ▸ | JAK1 | P23458 | 9/20 | 0.49 |
| ▸ | TYK2 | P29597 | 9/20 | 0.49 |
| ▸ | JAK3 | P52333 | 9/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373171 | 0.83 | CHEK1 (0.50) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606464 | 0.81 | CHEK1 (0.51) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL4497476 | 0.81 | JAK2 (0.49) | JAK2JAK1TYK2JAK3MAP4K4 | |
| SCHEMBL14543516 | 0.76 | JAK2 (0.51) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613574 | 0.76 | JAK2 (0.47) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL4499602 | 0.76 | JAK2 (0.47) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606562 | 0.76 | JAK2 (0.68) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL5469860 | 0.76 | JAK2 (0.73) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL4513320 | 0.76 | JAK2 (0.45) | CHEK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613448 | 0.75 | JAK2 (0.55) | CHEK1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1745050-A1 | THIENOPYRIDINES AS IKK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050272762-A1 | Thienopyridines as IKK inhibitors | ROCHE PALO ALTO LLC | 2005-12-08 | — | — | US | disclosed |
| WO-2005105809-A1 | THIENOPYRIDINES AS IKK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272762-A1 | Thienopyridines as IKK inhibitors | NFKBIA, IKBKE, IKBKB | CHEK1 263/4885JAK2 85/4885JAK1 48/4885 |
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CHEK1 3814/4885JAK2 1101/4885JAK1 1726/4885 |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | NFKBIA, IKBKE, IKBKB | CHEK1 263/4885JAK2 85/4885JAK1 48/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CHEK1 3814/4885JAK2 1101/4885JAK1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.